ALISO VIEJO, Calif., Feb. 17, 2011 /PRNewswire/ —
AVANIR Pharmaceuticals, Inc. (Nasdaq:
AVNR) today announced the promotion of Gregory J. Flesher to
the position of Senior Vice President of Corporate Development and
Chief Business Officer. In this role, Mr. Flesher will
oversee corporate strategy, business development, program
management, and business operations.
“Greg has shown exceptional leadership over the past several
years and has played a key role in the transformation of AVANIR
into a commercial-stage organization,” said Keith Katkin, President
and Chief Executive Officer. “His broad pharmaceutical
background in business development, sales and marketing, and
research and development provides a strong foundation which will
help AVANIR grow into a successful CNS company. I look
forward to Greg’s continued contributions to the executive
management team.”
Mr. Flesher has over 16 years of experience in the
pharmaceutical industry. He was previously Vice President of
Business Development for AVANIR, with responsibility for business
transactions, intellectual property, and NUEDEXTA™ lifecycle
planning. Prior to joining the Company, he held various
positions of increasing responsibility at InterMune Inc., Amgen
Inc., and Eli Lilly and Company.
Mr. Flesher graduated from Purdue University with a degree in
Biology and has completed his doctorate coursework in Biochemistry
and Molecular Biology at Indiana University School of Medicine.
About AVANIR Pharmaceuticals, Inc.
AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company
focused on bringing innovative medicines to patients with central
nervous system disorders of high unmet medical need. As part of our
commitment, we have extensively invested in our pipeline and are
dedicated to advancing medicines that can s
‘/>”/>
